ESC 365 - AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting

HFA Premium Access

AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting

Session: Late-Breaking Trials 2

Topic: Pharmacotherapy

Speaker: Professor P. Mc Ewan (Cardiff, GB)

Event: Heart Failure 2021

Congress Presentation

Add to my library

About the speaker

Professor Phil Mc Ewan

Health Economics and Outcomes Research Ltd, Cardiff (United Kingdom of Great Britain & Northern Ireland)

2 presentations

0 follower

2 more presentations in this session

Improving cognitive function in patients with heart failure - The Cognitive Training in Heart Failure Study (CogTrain-HF)

Speaker: Miss S. Wedegaertner (Homburg, DE)

Vericiguat in patients with atrial fibrilation and heart failure with reduced ejection fraction: insights from the VICTORIA (VerICiguaT global study in subjects with HFrEF)

Speaker: Professor P. Ponikowski (Wroclaw, PL)

Access the full session

Late-Breaking Trials 2

Speakers: Professor P. Mc Ewan, Miss S. Wedegaertner, Professor P. Ponikowski

About the event

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources